Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension
- PMID: 20713898
- DOI: 10.1161/CIRCULATIONAHA.109.933762
Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension
Abstract
Background: Inflammation is a feature of pulmonary arterial hypertension (PAH), and increased circulating levels of cytokines are reported in patients with PAH. However, to date, no information exists on the significance of elevated cytokines or their potential as biomarkers. We sought to determine the levels of a range of cytokines in PAH and to examine their impact on survival and relationship to hemodynamic indexes.
Methods and results: We measured levels of serum cytokines (tumor necrosis factor-alpha, interferon-gamma and interleukin-1beta, -2, -4, -5, -6, -8, -10, -12p70, and -13) using ELISAs in idiopathic and heritable PAH patients (n=60). Concurrent clinical data included hemodynamics, 6-minute walk distance, and survival time from sampling to death or transplantation. Healthy volunteers served as control subjects (n=21). PAH patients had significantly higher levels of interleukin-1beta, -2, -4, -6, -8, -10, and -12p70 and tumor necrosis factor-alpha compared with healthy control subjects. Kaplan-Meier analysis showed that levels of interleukin-6, 8, 10, and 12p70 predicted survival in patients. For example, 5-year survival with interleukin-6 levels of >9 pg/mL was 30% compared with 63% for patients with levels < or = 9 pg/mL (P=0.008). In this PAH cohort, cytokine levels were superior to traditional markers of prognosis such as 6-minute walk distance and hemodynamics.
Conclusions: This study illustrates dysregulation of a broad range of inflammatory mediators in idiopathic and familial PAH and demonstrates that cytokine levels have a previously unrecognized impact on patient survival. They may prove to be useful biomarkers and provide insight into the contribution of inflammation in PAH.
Comment in
-
Letter by Montani et al regarding article, "Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension".Circulation. 2011 May 31;123(21):e614; author reply e615. doi: 10.1161/CIRCULATIONAHA.110.991596. Circulation. 2011. PMID: 21632514 No abstract available.
Similar articles
-
Plasma markers in pulmonary hypertension subgroups correlate with patient survival.Respir Res. 2021 May 4;22(1):137. doi: 10.1186/s12931-021-01716-w. Respir Res. 2021. PMID: 33947407 Free PMC article.
-
Soluble TWEAK predicts hemodynamic impairment and functional capacity in patients with pulmonary arterial hypertension.Clin Res Cardiol. 2011 Oct;100(10):879-85. doi: 10.1007/s00392-011-0318-z. Epub 2011 Apr 11. Clin Res Cardiol. 2011. PMID: 21479966
-
Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension.Circulation. 2017 Nov 21;136(21):2022-2033. doi: 10.1161/CIRCULATIONAHA.117.028351. Epub 2017 Sep 28. Circulation. 2017. PMID: 28972005 Free PMC article.
-
Genetics and genomics of pulmonary arterial hypertension.J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D13-21. doi: 10.1016/j.jacc.2013.10.035. J Am Coll Cardiol. 2013. PMID: 24355637 Review.
-
Idiopathic pulmonary hypertension: what did we learn from genes?Sarcoidosis Vasc Diffuse Lung Dis. 2005 Dec;22 Suppl 1:S91-100. Sarcoidosis Vasc Diffuse Lung Dis. 2005. PMID: 16457021 Review.
Cited by
-
Pathobiology of pulmonary arterial hypertension and right ventricular failure.Eur Respir J. 2012 Dec;40(6):1555-65. doi: 10.1183/09031936.00046612. Epub 2012 Jun 27. Eur Respir J. 2012. PMID: 22743666 Free PMC article. Review.
-
Important Role of Endogenous Nerve Growth Factor Receptor in the Pathogenesis of Hypoxia-Induced Pulmonary Hypertension in Mice.Int J Mol Sci. 2023 Jan 18;24(3):1868. doi: 10.3390/ijms24031868. Int J Mol Sci. 2023. PMID: 36768190 Free PMC article.
-
Obesity and Pulmonary Hypertension.Curr Hypertens Rep. 2018 Oct 5;20(12):99. doi: 10.1007/s11906-018-0899-2. Curr Hypertens Rep. 2018. PMID: 30291516 Review.
-
Pirfenidone ameliorates pulmonary arterial pressure and neointimal remodeling in experimental pulmonary arterial hypertension by suppressing NLRP3 inflammasome activation.Pulm Circ. 2022 Jul 1;12(3):e12101. doi: 10.1002/pul2.12101. eCollection 2022 Jul. Pulm Circ. 2022. PMID: 35833096 Free PMC article.
-
Schistosome infection and its effect on pulmonary circulation.Glob Cardiol Sci Pract. 2019 Mar 31;2019(1):5. doi: 10.21542/gcsp.2019.5. Glob Cardiol Sci Pract. 2019. PMID: 31024947 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous